Unveiling the Molecular Mechanisms of Natural Triterpenoids From Mushrooms Against Type 2 Diabetes: A Critical Review
Phytotherapy Research · 2025-08 · 39 (8) · 3466-3485
DOI: 10.1002/ptr.70030 ↗At a glance
Übersichtsarbeit in Phytotherapy Research, published online on 2025-07-03. Written by Nidesha Randeni and 2 co-authors. Institution: Food Science and Technology Program, Department of Life Sciences, Beijing Normal-Hong Kong Baptist University, Zhuhai, Guangdong, China. Major MEDLINE topics: Diabetes Mellitus, Type 2, Triterpenes, Agaricales, Hypoglycemic Agents. Cited 7 times so far (Crossref); 132 references. Funded by: Beijing Normal-Hong Kong Baptist University.
Topics: Diabetes mellitus
Abstract (original language)
The exploration of triterpenoids derived from medicinal mushrooms presents an emerging frontier in managing type 2 diabetes (T2D). Triterpenoids achieve their therapeutic potential by targeting multiple pathways implicated in T2D pathology, including insulin resistance, chronic inflammation, and oxidative stress. This review critically summarizes the mechanisms by which mushroom‐derived triterpenoids, such as ganoderic acid, betulinic acid, and pachymic acid, exert anti‐diabetic effects. The molecular mechanisms of triterpenoids derived from medicinal mushrooms include the activation of AMP‐activated protein kinase (AMPK) and phosphatidylinositol 3kinase (PI3K‐Akt) signaling pathways, enhancing insulin sensitivity and glucose uptake, as well as the inhibition of α‐glucosidase activity, thereby reducing postprandial hyperglycemia. Additionally, triterpenoids can alleviate insulin resistance and pancreatic β‐cell dysfunction through modulating oxidative stress and inflammation. Notably, triterpenoids influence gut microbiota composition, promoting a healthier microbial balance that supports glucose metabolism and overall metabolic health. While preclinical studies underscore the promising potential of triterpenoids in T2D intervention, further high‐quality clinical trials are needed to validate the mushroom‐derived triterpenoids' clinical efficacy firmly. This review synthesizes these findings to establish a comprehensive framework for further research and product development of medical mushrooms.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Food Science and Technology Program, Department of Life Sciences, Beijing Normal-Hong Kong Baptist University, Zhuhai, Guangdong, China.
Funding
- Beijing Normal-Hong Kong Baptist University
Cite
APA
Randeni, N., Luo, J., & Xu, B. (2025). Unveiling the Molecular Mechanisms of Natural Triterpenoids From Mushrooms Against Type 2 Diabetes: A Critical Review. Phytotherapy Research, 39(8), 3466-3485. https://doi.org/10.1002/ptr.70030
Vancouver
Randeni N, Luo J, Xu B. Unveiling the Molecular Mechanisms of Natural Triterpenoids From Mushrooms Against Type 2 Diabetes: A Critical Review. Phytotherapy Research. 2025;39(8):3466-3485. doi:10.1002/ptr.70030
BibTeX
@article{Randeni2025,
author = {Randeni, Nidesha and Luo, Jinhai and Xu, Baojun},
title = {Unveiling the Molecular Mechanisms of Natural Triterpenoids From Mushrooms Against Type 2 Diabetes: A Critical Review},
journal = {Phytotherapy Research},
year = {2025},
volume = {39},
number = {8},
pages = {3466--3485},
doi = {10.1002/ptr.70030}
}
EUVIMED